Tevogen Bio Holdi…
USUSDTevogen Bio Holdings Inc. (US:TVGN) — Biotechnology: Biological Products (No Diagnostic Substances). Börside arv, kus ettevõtte aktsiatega kaubeldakse: 1. Sellel lehel — hind ja graafik, dividendid, suurimad aktsionärid ja aktsiate arvu ajalugu.
Ettevõtte Kohta
- Veebileht
- tevogen.com
- Sektor
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Peakontor
- WARREN, United States
- Tegevjuht
- Ryan H. Saadi
- Töötajad
- 18
- Ringluses Olevad Aktsiad
- 6.51 mln seisuga 2026-08-10
- Vabalt Kaubeldavad Aktsiad
- 843 310
- Turukapitalisatsioon
- 45.45 mln USD
- Siseringi Isikud
- 72.08%
- Institutsionaalsed Investorid
- 1.65%
- Tegevusala (SIC)
- Biological Products, (No Diagnostic Substances)
- P/E
- kahjum
- FCF
- −12.4 mln USD
- Võlg
- 1.01 mln USD
- Kasum ja FCF — 12 kuu jooksul kuni 30.06.2026 (ettevõtte viimane raport).
- NAV
Kirjeldus
Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920, a preclinical trial drug for treating cervical cancer; TVGN 960, a preclinical trial drug for treating oropharyngeal cancer; TVGN 601, a preclinical trial drug for treating multiple sclerosis; TVGN 930, a preclinical trial drug for treating Epstein-Barr virus associated lymphomas; and TVGN 116, a product candidate targeted at hepatitis B. It also offers artificial intelligence platform for drug development. Tevogen Inc. was formerly known as Tevogen Bio Holdings Inc. and changed its name to Tevogen Inc. in July 2026. The company was incorporated in 2020 and is headquartered in Warren, New Jersey.
Börsid ja Tikkerid
| Börs | Tikker | Valuuta | Hind | Tüüp |
|---|---|---|---|---|
| US USA Stocks | TVGN | USD | 7.08 +8.83% | tavalised aktsiad |
Suurimad Omanikud
| Omanik | Osalus | Aktsiad | Aruande Kuupäev |
|---|---|---|---|
| KHAN SADIQ (Officer) | ≈17.96% | 1.17 mln | 2025-06-27 |
| DESAI KIRTI (Chief Finan… | ≈15.25% | 992 983 | 2026-09-14 |
| PATTON CURTIS L (Directo… | ≈2.14% | 139 192 | 2026-09-11 |
| FEIKE JEFFREY L (Directo… | ≈2.02% | 131 435 | 2026-09-11 |
| SORDILLO VICTOR J (Direc… | ≈1.94% | 126 539 | 2026-09-11 |
| GOH KEOW LIN (Director) | ≈1.9% | 123 678 | 2026-09-11 |
| PODLOGAR SUSAN M (Direct… | ≈1.9% | 123 678 | 2026-09-11 |
| FLOMENBERG NEAL (Officer… | ≈1.18% | 76 940 | 2026-03-13 |
| Vanguard Capital Managem… | 0.15% | 23 976 | 2026-06-30 |
| Morgan Stanley | 0.12% | 18 809 | 2026-06-30 |
| AQR Capital Management,… | 0.11% | 17 237 | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 0.1% | 15 102 | 2026-06-30 |
| Goldman Sachs Group Inc | 0.09% | 14 163 | 2026-06-30 |
| GOLDMAN SACHS TRUST-Gold… | 0.09% | 13 951 | 2026-06-30 |
| Jane Street Group, LLC | 0.07% | 11 175 | 2026-06-30 |
| FMR, LLC | 0.06% | 9 826 | 2026-06-30 |
| VANGUARD Inst. INDEX Fd.… | 0.04% | 7 035 | 2026-06-30 |
| Russell Investments Grou… | 0.04% | 6 532 | 2026-06-30 |
| Fidelity Concord Street… | 0.03% | 4 081 | 2026-07-31 |
| VANGUARD SCOTTSDALE FUND… | 0.03% | 4 053 | 2026-05-31 |
| VANGUARD INDEX FUNDS-Van… | 0.01% | 1 839 | 2026-06-30 |
| Tower Research Capital L… | 0.01% | 1 494 | 2026-06-30 |
| Fidelity Concord Street… | 0.01% | 1 463 | 2026-07-31 |
| UBS Group AG | 0.01% | 1 083 | 2026-06-30 |
| Vanguard Fiduciary Trust… | 0.01% | 838 | 2026-06-30 |
| Fidelity Concord Street… | 0% | 357 | 2026-07-31 |
| VANGUARD SCOTTSDALE FUND… | 0% | 314 | 2026-05-31 |
| Fidelity Concord Street… | 0% | 300 | 2026-07-31 |
| SAADI RYAN H (Chief Exec… | — | 11.71 mln | 2026-09-14 |
Logi Sisse Google